UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back
Two Other Vaccines Show Promise
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.